Genomic Tests in Prostate Cancer Care
Author Information
Author(s): Roidos Christos, Anastasiadis Anastasios, Tsiakaras Stavros, Loutradis Charalampos, Baniotis Panagiotis, Memmos Dimitrios, Dimitriadis Georgios, Papaioannou Maria
Primary Institution: Aristotle University of Thessaloniki
Hypothesis
The review aims to evaluate the prognostic value and clinical use of genomic tests in intermediate-risk prostate cancer patients.
Conclusion
Genomic tests like Prolaris®, Oncotype DX®, and Decipher® show promise in improving risk stratification and treatment decision-making for prostate cancer patients.
Supporting Evidence
- Prolaris® has a strong correlation with biochemical recurrence and prostate cancer-specific mortality.
- Oncotype DX® provides important prognostic information that can guide clinical decision-making.
- Decipher® is associated with conservative management and predicts the need for radiation after surgery.
Takeaway
This study looks at tests that help doctors understand how serious prostate cancer is and how to treat it better.
Methodology
The review analyzed literature from PubMed and Cochrane Library on four genomic tests used in prostate cancer.
Potential Biases
Potential biases from retrospective data and questionnaire-based methods.
Limitations
The studies included varied in design and sample size, and many relied on retrospective data, which may introduce biases.
Participant Demographics
The studies included a diverse population of men with prostate cancer, but specific demographics were not detailed.
Statistical Information
P-Value
p<0.001
Confidence Interval
95%
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website